Nervgen Pharma Corp Stock Today

NGEN Stock  CAD 2.92  0.06  2.01%   

Performance

8 of 100

 
Weak
 
Strong
OK

Odds Of Distress

Over 59

 
High
 
Low
Above Average
NervGen Pharma is selling for under 2.92 as of the 18th of July 2024; that is 2.01% down since the beginning of the trading day. The stock's lowest day price was 2.92. NervGen Pharma has over 59 % chance of experiencing financial distress in the next 2 years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for NervGen Pharma Corp are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 18th of June 2024 and ending today, the 18th of July 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
Category
Healthcare
Classification
Health Care
NervGen Pharma Corp., a regenerative medicine company, engages in the discovery, development, and commercialization of therapeutics for the treatment of nerve damage, including spinal cord injuries and peripheral nerve injuries. The company was incorporated in 2017 and is based in Vancouver, Canada. The company has 69.93 M outstanding shares of which 115.46 K shares are now shorted by private and institutional investors with about 1.1 days to cover all short positions. More on NervGen Pharma Corp

Moving together with NervGen Stock

  0.82AMZN Amazon CDRPairCorr
  0.81AAPL Apple Inc CDRPairCorr
  0.72GOOG Alphabet CDR Earnings Call This WeekPairCorr
  0.67WMT Walmart Inc CDRPairCorr
  0.79MSFT Microsoft Corp CDRPairCorr
  0.62JPM JPMorgan ChasePairCorr

Moving against NervGen Stock

  0.35CHEV CHEVRON CDRPairCorr

NervGen Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. NervGen Pharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding NervGen Pharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
President CEOMichael Kelly
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
NervGen Pharma's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to NervGen Pharma's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Debt Levels
NervGen Pharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand NervGen Pharma's financial leverage. It provides some insight into what part of NervGen Pharma's total assets is financed by creditors.
Liquidity
NervGen Pharma cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. NervGen Pharma Corp has accumulated 15.25 M in total debt. NervGen Pharma Corp has a current ratio of 25.21, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist NervGen Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, NervGen Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like NervGen Pharma Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for NervGen to invest in growth at high rates of return. When we think about NervGen Pharma's use of debt, we should always consider it together with cash and equity.

Total Cash From Operating Activities

(11.86 Million)
NervGen Pharma Corp (NGEN) is traded on TSX Venture Exchange in Canada and employs 5 people. NervGen Pharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 204.19 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate NervGen Pharma's market, we take the total number of its shares issued and multiply it by NervGen Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. NervGen Pharma Corp operates under Biotechnology sector and is part of Health Care industry. The entity has 69.93 M outstanding shares of which 115.46 K shares are now shorted by private and institutional investors with about 1.1 days to cover all short positions. NervGen Pharma Corp has accumulated about 8.27 M in cash with (11.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.3.
Check NervGen Pharma Probability Of Bankruptcy
Ownership Allocation
NervGen Pharma Corp maintains a total of 69.93 Million outstanding shares. NervGen Pharma Corp holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check NervGen Ownership Details

NervGen Pharma Corp Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. NervGen Pharma market risk premium is the additional return an investor will receive from holding NervGen Pharma long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in NervGen Pharma. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although NervGen Pharma's alpha and beta are two of the key measurements used to evaluate NervGen Pharma's performance over the market, the standard measures of volatility play an important role as well.

NervGen Stock Against Markets

Be your own money manager

Our tools can tell you how much better you can do entering a position in NervGen Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Economic Indicators Now

   

Economic Indicators

Top statistical indicators that provide insights into how an economy is performing
All  Next Launch Module

Additional Tools for NervGen Stock Analysis

When running NervGen Pharma's price analysis, check to measure NervGen Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NervGen Pharma is operating at the current time. Most of NervGen Pharma's value examination focuses on studying past and present price action to predict the probability of NervGen Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NervGen Pharma's price. Additionally, you may evaluate how the addition of NervGen Pharma to your portfolios can decrease your overall portfolio volatility.